[go: up one dir, main page]

SG11201509665XA - Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells - Google Patents

Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Info

Publication number
SG11201509665XA
SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA
Authority
SG
Singapore
Prior art keywords
tacrolimus
treating diseases
neuronal cells
protein aggregate
diseases characterised
Prior art date
Application number
SG11201509665XA
Inventor
Alexandre Akoulitchev
Elizabeth Milway
Elizabeth Jane Mellor
Michael Youdell
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Publication of SG11201509665XA publication Critical patent/SG11201509665XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201509665XA 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells SG11201509665XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1309375.2A GB201309375D0 (en) 2013-05-24 2013-05-24 Medical methods and compounds for medical use
PCT/GB2014/051570 WO2014188197A1 (en) 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Publications (1)

Publication Number Publication Date
SG11201509665XA true SG11201509665XA (en) 2015-12-30

Family

ID=48784691

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509665XA SG11201509665XA (en) 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Country Status (8)

Country Link
US (1) US20160296500A1 (en)
EP (1) EP3003304A1 (en)
JP (2) JP2016528171A (en)
KR (1) KR20160012184A (en)
CA (1) CA2910006A1 (en)
GB (1) GB201309375D0 (en)
SG (1) SG11201509665XA (en)
WO (1) WO2014188197A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600376D0 (en) * 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
CN110869054B (en) * 2017-07-04 2022-06-07 比诺斯生物科技有限公司 Use of macrocyclic azapyridinylcyclophane metal complexes in the treatment of disease
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
JPWO2023085363A1 (en) * 2021-11-12 2023-05-19

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
FR2810995A1 (en) * 2000-06-29 2002-01-04 Exonhit Therapeutics Sa COMPOSITIONS AND METHODS FOR THE TREATMENT OR DETECTION OF NEURODEGENERATIVE CONDITIONS
AR035411A1 (en) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE
GB0410101D0 (en) * 2004-05-06 2004-06-09 Leuven K U Res & Dev Parkinson's disease
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
JP2012171895A (en) * 2011-02-18 2012-09-10 Nagoya City Univ Therapeutic agent for ataxia telangiectasia and application of the same

Also Published As

Publication number Publication date
JP2016528171A (en) 2016-09-15
WO2014188197A1 (en) 2014-11-27
US20160296500A1 (en) 2016-10-13
CA2910006A1 (en) 2014-11-27
GB201309375D0 (en) 2013-07-10
JP2019104746A (en) 2019-06-27
EP3003304A1 (en) 2016-04-13
KR20160012184A (en) 2016-02-02

Similar Documents

Publication Publication Date Title
IL267609B (en) Bet protein inhibitors in combination with janus kinase inhibitors for the treatment of proliferative diseases
LT3542798T (en) Aceclidine for use in the treatment of presbyopia
ZA201603332B (en) Gla monotherapy for use in cancer treatment
HUE068364T2 (en) Factor 1 protein for use in treating or preventing diseases
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3060237T3 (en) Modified reprogramming protein for use in treating a cancer
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
SMT202000164T1 (en) Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
SG11201505460WA (en) Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
EP2849785A4 (en) Methods for treating cancer with notch2/3 antibodies
EP2904014A4 (en) Alternative pathway specific antibodies for treating hemolytic diseases
IL232791A0 (en) Methods for the treating hyperbilirubinemia with stannsoporfin
IL274047B (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
IL245541A0 (en) Novel methods for treating neurodegenerative diseases
SG11201509665XA (en) Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells
IL236714A0 (en) Anri-her2 antibodies with low fucosylation for use in treating cancer
IL239078A0 (en) Protein for use in the treatment of ocular diseases
PT2836176T (en) Technique for treating presbyopia
IL236505B (en) Enoxacin for use in treating motor neuron diseases
ZA201302565B (en) Methods for treating hyperuricemia and related diseases
HK1228736A1 (en) Novel methods for treating neurodegenerative diseases
HUE048942T2 (en) Anthracyline derivatives for treating tumor diseases